- Home
- AKYA vs MGX Comparison
AKYA vs MGX Comparison
Compare AKYA & MGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKYA
- MGX
- Stock Information
- Founded
- AKYA 2015
- MGX 2018
- Country
- AKYA United States
- MGX United States
- Employees
- AKYA N/A
- MGX N/A
- Industry
- AKYA Medical Specialities
- MGX
- Sector
- AKYA Industrials
- MGX
- Exchange
- AKYA Nasdaq
- MGX NYSE
- Market Cap
- AKYA 56.1M
- MGX 62.1M
- IPO Year
- AKYA 2021
- MGX 2024
- Fundamental
- Price
- AKYA $1.24
- MGX $1.79
- Analyst Decision
- AKYA Hold
- MGX Strong Buy
- Analyst Count
- AKYA 7
- MGX 4
- Target Price
- AKYA $2.51
- MGX $13.00
- AVG Volume (30 Days)
- AKYA 1.1M
- MGX 297.1K
- Earning Date
- AKYA 05-12-2025
- MGX 05-13-2025
- Dividend Yield
- AKYA N/A
- MGX N/A
- EPS Growth
- AKYA N/A
- MGX N/A
- EPS
- AKYA N/A
- MGX N/A
- Revenue
- AKYA $79,961,000.00
- MGX $45,263,000.00
- Revenue This Year
- AKYA $12.57
- MGX N/A
- Revenue Next Year
- AKYA $13.73
- MGX $8.34
- P/E Ratio
- AKYA N/A
- MGX N/A
- Revenue Growth
- AKYA N/A
- MGX N/A
- 52 Week Low
- AKYA $0.93
- MGX $1.23
- 52 Week High
- AKYA $3.42
- MGX $6.90
- Technical
- Relative Strength Index (RSI)
- AKYA 52.88
- MGX 57.24
- Support Level
- AKYA $1.21
- MGX $1.59
- Resistance Level
- AKYA $1.26
- MGX $1.82
- Average True Range (ATR)
- AKYA 0.08
- MGX 0.11
- MACD
- AKYA 0.02
- MGX 0.02
- Stochastic Oscillator
- AKYA 60.71
- MGX 88.61
About AKYA Akoya BioSciences Inc.
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.